Anzeige
Mehr »
Login
Montag, 31.03.2025 Börsentäglich über 12.000 News von 695 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2P208 | ISIN: US68622P1093 | Ticker-Symbol: 4TZ
Tradegate
31.03.25
21:18 Uhr
5,150 Euro
-0,550
-9,65 %
Branche
Pharma
Aktienmarkt
NASDAQ Biotech
1-Jahres-Chart
ORIC PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
ORIC PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
5,1005,25022:03
5,1505,20022:00

Aktuelle News zur ORIC PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiORIC Pharmaceuticals: ORIC Pharmaceuticals Announces ORIC-944 Preclinical Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting1
22.03.ORIC Pharmaceuticals (NASDAQ:ORIC) Trading Down 4.9% - Here's What Happened4
20.03.Oric Pharmaceuticals, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
14.03.Oric Pharmaceuticals, Inc. - 8-K, Current Report3
07.03.ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)129SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 07, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address...
► Artikel lesen
25.02.ORIC Pharmaceuticals: ORIC Pharmaceuticals Announces Focused Registrational Clinical Development Plans for Lead Programs, Extended Cash Runway, and Updated Corporate Milestones85Anticipated registrational development plans for ORIC-944 and ORIC-114 prioritized to focus on indications with strongest clinical validation and highest unmet need ORIC-944 initiation of first Phase...
► Artikel lesen
ORIC PHARMACEUTICALS Aktie jetzt für 0€ handeln
25.02.Oric Pharmaceuticals, Inc. - 8-K, Current Report-
22.02.HC Wainwright Reaffirms "Buy" Rating for ORIC Pharmaceuticals (NASDAQ:ORIC)3
18.02.ORIC Pharmaceuticals: ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates92Reported encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with androgen receptor inhibitors in patients with mCRPC Entered into clinical...
► Artikel lesen
18.02.Oric Pharmaceuticals, Inc. - 10-K, Annual Report1
18.02.Oric Pharmaceuticals, Inc. - 8-K, Current Report-
18.02.Stifel maintains $20 target on ORIC shares, reiterates Buy rating2
11.02.ORIC Pharmaceuticals stock target holds at $21 by H.C. Wainwright1
10.02.Jones Trading maintains Buy on ORIC, $17 target on positive data2
10.02.Cantor Fitzgerald maintains Overweight on ORIC stock2
10.02.ORIC Pharmaceuticals shares surge on potential data leak2
10.02.ORIC Pharmaceuticals-Aktien steigen aufgrund möglicher Datenlecks2
10.02.Guggenheim Reiterates "Buy" Rating for ORIC Pharmaceuticals (NASDAQ:ORIC)1
07.02.ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)123SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb. 07, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address...
► Artikel lesen
04.02.Cantor Fitzgerald maintains Overweight on ORIC shares, sees upside2
Seite:  Weiter >>
43 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1